Details of the Drug Combination

General Information of Drug Combination (ID: DCGA5J7)

Drug Combination Name
MK-1775 Ridaforolimus
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs MK-1775   DM3WDZ5 Ridaforolimus   DMLHEU7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: A375
Zero Interaction Potency (ZIP) Score: 3.07
Bliss Independence Score: 2.16
Loewe Additivity Score: 0.16
LHighest Single Agent (HSA) Score: 4.25

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [5]
------------------------------------------------------------------------------------
Indication(s) of Ridaforolimus
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [4]
Ridaforolimus Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCT7IN2 CAOV3 Investigative [1]
Adenocarcinoma DCS8YOH NCIH2122 Investigative [1]
Adenocarcinoma DC52I6V HCT116 Investigative [1]
Adenocarcinoma DCU728B HT29 Investigative [1]
Amelanotic melanoma DCFRRQC A2058 Investigative [1]
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCJXCKO ES2 Investigative [1]
Germ cell tumour DCMVRXJ PA1 Investigative [1]
Malignant melanoma DCPG0HL SKMEL30 Investigative [1]
Mesothelioma DCZRS2V MSTO Investigative [1]
Non small cell carcinoma DCMF756 SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DC5YV74 A2780 Investigative [1]
Prostate carcinoma DCX10HL LNCAP Investigative [1]
Prostate carcinoma DCOSCKI VCAP Investigative [1]
Breast carcinoma DC0IBEJ KPL1 Investigative [7]
Colon adenocarcinoma DCI0DOY LOVO Investigative [7]
Colon carcinoma DCYKCYG RKO Investigative [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
5 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
6 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
7 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.